Abstract 2391P
Background
Micropapillary urothelial carcinoma (MUC) is a rare and aggressive histological variant with poor clinical outcomes and limited consensus regarding its management. The mainstay of treatment in muscle-invasive disease is radical cystectomy (RC). Data regarding the role of neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) in muscle-invasive MUC is limited.
Methods
The United States National Cancer Database was queried for patients (pts) with MUC diagnosed from 2004 to 2018. Pts older than 18 years with cT2-4aN0-1M0 MUC who underwent RC were included. Clinical T4b/N2-3/M1 and receipt of NAC+AC were used as exclusion criteria. The pts were divided into three cohorts based on perioperative therapy- NAC, AC, and no chemotherapy (CX-). Chi-Square and Kruskal-Wallis tests were used to compare frequency distributions. Cox Proportional Hazards regression was employed to adjust for confounders associated with overall survival (OS). Models were adjusted for age, race, sex, stage, insurance, and comorbidities.
Results
Of the 477 pts included, 80% were males, and 93% were White. 103 (21.6%) and 157 (32.9%) received NAC and AC, respectively, while 217 (45.5%) belonged to the CX- group. Pts in the NAC & AC groups were younger (66 yrs vs 73 yrs in CX-, p<0.001). OS was longer in the NAC and AC groups (Table). However, on multivariable analysis, NAC was predictive of OS (Hazard Ratio (HR) 0.68, 95% CI 0.47-0.97, p = 0.03) while AC was not (HR 0.84, 95% CI 0.63-1.12, p =0.22). In a separate Cox model, pT0-1N0 disease was independently associated with improved OS (HR 0.27, 95% CI 0.12-0.61, p=0.002). The NAC group had significantly more pT0N0 (14.8% vs 2.8%, p<0.001) & pT0-1N0 (21% vs 5.9%, p<0.001) disease at RC compared to the combined cohort of AC+CX-.
Table: 2391P
Cohort | Median OS (months) | 3-year OS (%) | 5-year OS (%) | Median follow-up (months) | Log-rank P |
CX- | 23.1 (18.1-28.7) | 40 (30-47) | 34 (27-41) | 68.7 | 0.008 |
AC | 34.0 (25.7-59.2) | 49 (40-57) | 40 (31-49) | 51.5 | |
NAC | 56.4 (30.1-NR) | 55 (43-65) | 45 (33-57) | 46.4 |
Conclusions
In this large retrospective analysis, NAC was independently predictive of longer OS in muscle-invasive MUC, while AC was not. NAC was also associated with pathological downstaging.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.M. Roy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2402P - Urine-based comprehensive genomic profiling reveals mutational landscape in real-world patients with bladder cancer
Presenter: Haige Chen
Session: Poster session 24
2403P - CDKN2A deletions are a mechanism for p16 inactivation in urothelial bladder carcinomas and are associated with an aggressive tumor phenotype
Presenter: Martina Kluth
Session: Poster session 24
2404P - Concordance of genomic alterations by next-generation sequencing in tumor tissue versus urinary tumor DNA and circulating tumor DNA in bladder cancer
Presenter: Song Xue
Session: Poster session 24
2405P - Prognostic significance of circulating tumor DNA in patients with urothelial carcinoma: A systematic review and meta-analysis
Presenter: Liu Haoyang
Session: Poster session 24
2407TiP - SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
Presenter: Andrea Necchi
Session: Poster session 24
2408TiP - DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints
Presenter: Francesca Jackson-Spence
Session: Poster session 24
2409TiP - A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)
Presenter: Shilpa Gupta
Session: Poster session 24